60 Degrees Pharmaceuticals Plans to Seek FDA Priority Review Voucher for Tafenoquine in Babesiosis

60 DEGREES PHARMACEUTICALS, INC.

Company intends to apply for a Commissioner's National Priority Review Voucher if trial results support NDA submission by Q1 2028.
Tafenoquine is being evaluated in a randomized, placebo-controlled trial for patients hospitalized with severe babesiosis.
Application depends on interim or final analysis of the severe babesiosis trial supporting a New Drug Application.
Disclosure is provided to inform investors of current development and regulatory plans, subject to forward-looking risks.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.